12 November 2010

A nanoplast instead of an injection

RUSNANO will finance the expansion of the production of nanostructured biopolymer implants and the launch of transdermal drug delivery systems to combat socially significant diseases.

The applicant of the project was the company "BIOMIR service" – a Russian developer and manufacturer of innovative medical materials. The project is headed by Doctor of Biological Sciences, Professor Viktor Sevastyanov – Head of the Biomaterials Research Department of the Federal State University "Scientific Research Institute of Transplantology and Artificial Organs named after Academician V.I.Shumakov" and Director of the ANO "Institute of Biomedical Research and Technology".

The project will create the production of plasters for transdermal delivery of drugs. It is assumed that transdermal forms of insulin, propranolol, acetylsalicylic acid, chlorpropamide, lidocaine, caffeine, testosterone and acizole will be brought to the market. These substances are not able to penetrate the skin independently, therefore micro- and nanoscale micelles are used for their transport. The micelle surface is formed by lipid-like molecules, whose spatial orientation varies depending on the nature of the environment. This unique property allows the micelle to freely overcome the surface layers of the skin and release the medicinal substance directly into the bloodstream.

Thanks to the comfortable introduction of drugs, transdermal technologies will provide serious competition to traditional injections. This is especially true for the treatment of chronic diseases with lifelong binding of patients to taking medications, many of which are currently available only in the form of injections.

It is assumed that the transdermal medicinal patches produced under the project will occupy in their market segments from 1% (transdermal anti-inflammatory drugs) to 30% (the market of transdermal local painkillers). Transdermal injection technologies are particularly in demand for the delivery of protein molecules (for example, insulin), which are necessary for the treatment of socially significant diseases such as diabetes.

The total budget of the project will be 488.2 million rubles. RUSNANO will invest 225 million rubles in the form of a contribution of 128 million rubles to the authorized capital of the project company and a loan of 97 million rubles. The annual revenue of the project in 2015 is projected at the level of 685 million rubles.

Portal "Eternal youth" http://vechnayamolodost.ru according to the materials of the RUSNANO press service


Found a typo? Select it and press ctrl + enter Print version